These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 33933677)

  • 1. Dopamine D2 receptor agonist, bromocriptine, remodels adipose tissue dopaminergic signalling and upregulates catabolic pathways, improving metabolic profile in type 2 diabetes.
    Tavares G; Marques D; Barra C; Rosendo-Silva D; Costa A; Rodrigues T; Gasparini P; Melo BF; Sacramento JF; Seiça R; Conde SV; Matafome P
    Mol Metab; 2021 Sep; 51():101241. PubMed ID: 33933677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subcutaneous adipose tissue dopamine D2 receptor is increased in prediabetes and T2D.
    Vranic M; Ahmed F; Kristófi R; Hetty S; Mokhtari D; Svensson MK; Eriksson JW; Pereira MJ
    Endocrine; 2024 Feb; 83(2):378-391. PubMed ID: 37752366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence-based practice use of quick-release bromocriptine across the natural history of type 2 diabetes mellitus.
    Schwartz SS; Zangeneh F
    Postgrad Med; 2016 Nov; 128(8):828-838. PubMed ID: 27458683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peripheral Dopamine Directly Acts on Insulin-Sensitive Tissues to Regulate Insulin Signaling and Metabolic Function.
    Tavares G; Martins FO; Melo BF; Matafome P; Conde SV
    Front Pharmacol; 2021; 12():713418. PubMed ID: 34566639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bromocriptine administration reduces hyperphagia and adiposity and differentially affects dopamine D2 receptor and transporter binding in leptin-receptor-deficient Zucker rats and rats with diet-induced obesity.
    Davis LM; Michaelides M; Cheskin LJ; Moran TH; Aja S; Watkins PA; Pei Z; Contoreggi C; McCullough K; Hope B; Wang GJ; Volkow ND; Thanos PK
    Neuroendocrinology; 2009; 89(2):152-62. PubMed ID: 18984941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological modulation of dopamine receptor D2-mediated transmission alters the metabolic phenotype of diet induced obese and diet resistant C57Bl6 mice.
    de Leeuw van Weenen JE; Parlevliet ET; Schröder-van der Elst JP; van den Berg SA; Willems van Dijk K; Romijn JA; Pijl H
    Exp Diabetes Res; 2011; 2011():928523. PubMed ID: 21603181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of Novel Tools for Dissection of Central Versus Peripheral Dopamine D2-Like Receptor Signaling in Dysglycemia.
    Bonifazi A; Ellenberger M; Farino ZJ; Aslanoglou D; Rais R; Pereira S; Mantilla-Rivas JO; Boateng CA; Eshleman AJ; Janowsky A; Hahn MK; Schwartz GJ; Slusher BS; Newman AH; Freyberg Z
    Diabetes; 2024 Sep; 73(9):1411-1425. PubMed ID: 38869519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine D
    Wei H; Zapata RC; Lopez-Valencia M; Aslanoglou D; Farino ZJ; Benner V; Osborn O; Freyberg Z; McCarthy MJ
    Psychoneuroendocrinology; 2020 Mar; 113():104551. PubMed ID: 31884319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impaired brown adipose tissue is differentially modulated in insulin-resistant obese wistar and type 2 diabetic Goto-Kakizaki rats.
    Serdan TDA; Masi LN; Pereira JNB; Rodrigues LE; Alecrim AL; Scervino MVM; Diniz VLS; Dos Santos AAC; Filho CPBS; Alba-Loureiro TC; Marzuca-Nassr GN; Bazotte RB; Gorjão R; Pithon-Curi TC; Curi R; Hirabara SM
    Biomed Pharmacother; 2021 Oct; 142():112019. PubMed ID: 34403962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hemin therapy suppresses inflammation and retroperitoneal adipocyte hypertrophy to improve glucose metabolism in obese rats co-morbid with insulin-resistant type-2 diabetes.
    Ndisang JF; Jadhav A
    Diabetes Obes Metab; 2013 Nov; 15(11):1029-39. PubMed ID: 23731386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LMO3 reprograms visceral adipocyte metabolism during obesity.
    Wagner G; Fenzl A; Lindroos-Christensen J; Einwallner E; Husa J; Witzeneder N; Rauscher S; Gröger M; Derdak S; Mohr T; Sutterlüty H; Klinglmüller F; Wolkerstorfer S; Fondi M; Hoermann G; Cao L; Wagner O; Kiefer FW; Esterbauer H; Bilban M
    J Mol Med (Berl); 2021 Aug; 99(8):1151-1171. PubMed ID: 34018016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the alpha2-adrenergic receptors in beta cells.
    de Leeuw van Weenen JE; Parlevliet ET; Maechler P; Havekes LM; Romijn JA; Ouwens DM; Pijl H; Guigas B
    Biochem Pharmacol; 2010 Jun; 79(12):1827-36. PubMed ID: 20138024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diabetes and branched-chain amino acids: What is the link?
    Bloomgarden Z
    J Diabetes; 2018 May; 10(5):350-352. PubMed ID: 29369529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of dopamine D2 receptors simultaneously ameliorates various metabolic features of obese women.
    Kok P; Roelfsema F; Frölich M; van Pelt J; Stokkel MP; Meinders AE; Pijl H
    Am J Physiol Endocrinol Metab; 2006 Nov; 291(5):E1038-43. PubMed ID: 16803851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time-of-Day-Dependent Effects of Bromocriptine to Ameliorate Vascular Pathology and Metabolic Syndrome in SHR Rats Held on High Fat Diet.
    Ezrokhi M; Zhang Y; Luo S; Cincotta AH
    Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34200262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain Dopamine-Clock Interactions Regulate Cardiometabolic Physiology: Mechanisms of the Observed Cardioprotective Effects of Circadian-Timed Bromocriptine-QR Therapy in Type 2 Diabetes Subjects.
    Cincotta AH
    Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bromocriptine/SKF38393 treatment ameliorates obesity and associated metabolic dysfunctions in obese (ob/ob) mice.
    Cincotta AH; Tozzo E; Scislowski PW
    Life Sci; 1997; 61(10):951-6. PubMed ID: 9296333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic activity of sarpogrelate and dopamine D
    Fouad Shalaby MA; Abd El Latif HA; El Yamani M; Galal MA; Kamal S; Sindi I; Masaood R
    BMC Pharmacol Toxicol; 2021 Oct; 22(1):64. PubMed ID: 34702339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of long-term nitrate supplementation on carbohydrate metabolism, lipid profiles, oxidative stress, and inflammation in male obese type 2 diabetic rats.
    Gheibi S; Jeddi S; Carlström M; Gholami H; Ghasemi A
    Nitric Oxide; 2018 May; 75():27-41. PubMed ID: 29432804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurogenetics of dopaminergic receptor supersensitivity in activation of brain reward circuitry and relapse: proposing "deprivation-amplification relapse therapy" (DART).
    Blum K; Chen TJ; Downs BW; Bowirrat A; Waite RL; Braverman ER; Madigan M; Oscar-Berman M; DiNubile N; Stice E; Giordano J; Morse S; Gold M
    Postgrad Med; 2009 Nov; 121(6):176-96. PubMed ID: 19940429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.